[{"orgOrder":0,"company":"Sotio","sponsor":"Cytune Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CZECH REPUBLIC","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"SO-C101","moa":"IL-15 alpha receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Sotio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Sotio \/ Cytune Pharma","highestDevelopmentStatusID":"6","companyTruncated":"Sotio \/ Cytune Pharma"},{"orgOrder":0,"company":"Sotio","sponsor":"Unum Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Acquisition","leadProduct":"BOXR1030","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Sotio","amount2":0.01,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"","sponsorNew":"Sotio \/ SOTIO","highestDevelopmentStatusID":"4","companyTruncated":"Sotio \/ SOTIO"},{"orgOrder":0,"company":"Sotio","sponsor":"Cytune Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CZECH REPUBLIC","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"SO-C101","moa":"IL-15 alpha receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Sotio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Sotio \/ Cytune Pharma","highestDevelopmentStatusID":"6","companyTruncated":"Sotio \/ Cytune Pharma"},{"orgOrder":0,"company":"Sotio","sponsor":"LegoChem Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Large molecule","year":"2021","type":"Collaboration","leadProduct":"LCB20A","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Sotio","amount2":1.03,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":1.03,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Sotio \/ SOTIO","highestDevelopmentStatusID":"2","companyTruncated":"Sotio \/ SOTIO"},{"orgOrder":0,"company":"Sotio","sponsor":"PPF Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CZECH REPUBLIC","productType":"Large molecule","year":"2021","type":"Financing","leadProduct":"SOT101","moa":"IL-15","graph1":"Oncology","graph2":"Phase I","graph3":"Sotio","amount2":0.32000000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.32000000000000001,"dosageForm":"Subcutaneous","sponsorNew":"Sotio \/ PPF Group","highestDevelopmentStatusID":"6","companyTruncated":"Sotio \/ PPF Group"},{"orgOrder":0,"company":"Sotio","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CZECH REPUBLIC","productType":"Large molecule","year":"2021","type":"Collaboration","leadProduct":"SOT101","moa":"IL-15","graph1":"Oncology","graph2":"Phase I","graph3":"Sotio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous","sponsorNew":"Sotio \/ Merck","highestDevelopmentStatusID":"6","companyTruncated":"Sotio \/ Merck"},{"orgOrder":0,"company":"Sotio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CZECH REPUBLIC","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"SO-C101","moa":"IL-15 alpha receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Sotio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Sotio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sotio \/ Not Applicable"},{"orgOrder":0,"company":"Sotio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CZECH REPUBLIC","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"SOT101","moa":"IL-15 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Sotio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sotio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sotio \/ Not Applicable"},{"orgOrder":0,"company":"Sotio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"SOT101","moa":"IL-15 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Sotio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sotio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sotio \/ Not Applicable"},{"orgOrder":0,"company":"Sotio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"SOT101","moa":"IL-15","graph1":"Oncology","graph2":"Phase II","graph3":"Sotio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sotio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sotio \/ Not Applicable"},{"orgOrder":0,"company":"Sotio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"SOT101","moa":"IL-2","graph1":"Oncology","graph2":"Phase II","graph3":"Sotio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Sotio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sotio \/ Not Applicable"},{"orgOrder":0,"company":"Sotio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CZECH REPUBLIC","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"SOT101","moa":"IL-2","graph1":"Oncology","graph2":"Phase II","graph3":"Sotio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Sotio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sotio \/ Not Applicable"},{"orgOrder":0,"company":"Sotio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CZECH REPUBLIC","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"SOT101","moa":"IL-2","graph1":"Oncology","graph2":"Phase II","graph3":"Sotio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Sotio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sotio \/ Not Applicable"},{"orgOrder":0,"company":"Sotio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CZECH REPUBLIC","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Nanrilkefusp Alfa","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Sotio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Sotio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sotio \/ Not Applicable"},{"orgOrder":0,"company":"Sotio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CZECH REPUBLIC","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"SOT102","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sotio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sotio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Sotio \/ Not Applicable"},{"orgOrder":0,"company":"Sotio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CZECH REPUBLIC","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Nanrilkefusp Alfa","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Sotio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sotio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sotio \/ Not Applicable"},{"orgOrder":0,"company":"Sotio","sponsor":"Synaffix","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Large molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Sotio","amount2":0.73999999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.73999999999999999,"dosageForm":"","sponsorNew":"Sotio \/ SOTIO","highestDevelopmentStatusID":"4","companyTruncated":"Sotio \/ SOTIO"},{"orgOrder":0,"company":"Sotio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CZECH REPUBLIC","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"BOXR1030","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sotio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Sotio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Sotio \/ Not Applicable"},{"orgOrder":0,"company":"Sotio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CZECH REPUBLIC","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"SOT201","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Sotio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Sotio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sotio \/ Not Applicable"},{"orgOrder":0,"company":"Sotio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CZECH REPUBLIC","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"SO-N102","moa":"CLDN18.2","graph1":"Oncology","graph2":"Phase I","graph3":"Sotio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sotio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sotio \/ Inapplicable"},{"orgOrder":0,"company":"Sotio","sponsor":"LegoChem Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CZECH REPUBLIC","productType":"Antibody-drug Conjugate","year":"2022","type":"Agreement","leadProduct":"SOT106","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Sotio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sotio \/ LegoChem Biosciences","highestDevelopmentStatusID":"4","companyTruncated":"Sotio \/ LegoChem Biosciences"},{"orgOrder":0,"company":"Sotio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CZECH REPUBLIC","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"SO-N102","moa":"CLDN18.2","graph1":"Oncology","graph2":"Preclinical","graph3":"Sotio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sotio \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Sotio \/ Inapplicable"},{"orgOrder":0,"company":"Sotio","sponsor":"Biocytogen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2025","type":"Licensing Agreement","leadProduct":"SOT109","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Sotio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sotio \/ Sotio","highestDevelopmentStatusID":"4","companyTruncated":"Sotio \/ Sotio"}]
Find Clinical Drug Pipeline Developments & Deals by Sotio
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
